Anus Neoplasms clinical trials
The registry lists 297 studies for Anus Neoplasms across more than 10 countries. 74 are recruiting or about to start. 154 of them are mainly about Anus Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its narrower condition Anal Canal Carcinoma too: 313 studies, 78 open.
Get an email when these change. Save the Anus Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
National Cancer Institute (NCI) (23) · AIDS Malignancy Consortium (11) · M.D. Anderson Cancer Center (8) · Stanford University (6) · University Health Network, Toronto (5) · Memorial Sloan Kettering Cancer Center (5) · Sahlgrenska University Hospital (4) · Aarhus University Hospital (4)
What is being tested here
Drugs under test in Anus Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Drug classes tested here Immune checkpoint inhibitors 7 open · Antimetabolites 1 open · Alkylating agents 1 open · Antimitotic agents 1 open · Tyrosine kinase inhibitors (TKIs) 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Mar 2027EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients · Phase 3 · National Cancer Institute (NCI)
- Jul 2027A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males · Phase 3 · Shanghai Bovax Biotechnology Co., Ltd.
- Nov 2026Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma. · Centre Hospitalier Universitaire de Besancon
- Nov 2026Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus · Cardiff University
- Dec 2026Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma · SCG Cell Therapy Pte. Ltd.
- Dec 2026Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure Prophylaxis · Universitair Ziekenhuis Brussel
- Dec 2026Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls · National Cancer Institute (NCI)
- Dec 2026Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group · Goethe University
- Dec 2026Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer · Ohio State University Comprehensive Cancer Center
- Dec 2026Adaptive Radiation in Anal Cancer · Columbia University
Who these studies take
Of the 57 Anus Neoplasms studies recruiting now, 46 (81%) set no upper age limit and 7 (12%) stop at 75 or younger. 3 (5%) take children under 18. 7 (12%) are for women only and 2 (4%) for men only; 6 (11%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 2 (4%) | 1 (2%) |
| 18 | 50 (88%) | 47 (82%) |
| 30 | 51 (89%) | 47 (82%) |
| 40 | 54 (95%) | 49 (86%) |
| 50 | 55 (96%) | 49 (86%) |
| 65 | 55 (96%) | 49 (86%) |
| 75 | 54 (95%) | 48 (84%) |
| 85 | 48 (84%) | 42 (74%) |
Across all 297 studies, recruiting or not: 14% stop at 75 or younger and 7% at 65; 8% take children; 8% are for women only and 9% for men only; 12% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Anus Neoplasms studies take
Of 40 phase 2 interventional studies under Anus Neoplasms, half reached primary completion within 62 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 46 mo27–57 · 20 studies | — | — |
| Phase 2 | 62 mo42–105 · 40 studies | — | — |
| Interventional, no phase | 52 mo17–… · 39 studies | — | — |
| Observational | 44 mo32–137 · 36 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Newly registered1
- A Study of Retifanlimab After Chemoradiation in People With Anal CancerNov 10, 2026NCT07927998
Studies
Recruiting first, then most recently updated. Showing 50 of 297. Browse all 297 → or search them.
- A Study of Retifanlimab After Chemoradiation in People With Anal CancerRecruitingNCT07927998Phase 21 country
- Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal CancerRecruitingNCT06493019Phase 21 country
- Distance-Based Exercise to Preserve Function and Prevent DisabilityRecruitingNCT07059884Not applicable1 country
- E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated CancersRecruitingNCT05686226Phase 21 country
- E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated CancersRecruitingNCT05639972Phase 1/21 country
- SMP-3124LP in Adults With Advanced Solid TumorsRecruitingNCT06526819Phase 1/22 countries
- Stigma and Psychological profilE in REctal-anal caNcer pAtientsRecruitingNCT063668411 country
- Improving Clinic Delivery of HIV-related Anal Health ServicesNot yet recruitingNCT07464236Not applicable1 country
- Screening Women With Prior HPV for Anal NeoplasiaRecruitingNCT05217940Not applicable1 country
- COQ10 and Vitamin E for Off-Target Radiation ToxicityNot yet recruitingNCT07668284Phase 1/21 country
- Epidemiology of Anal Human Papillomavirus Carriage in Female Solid Organ Transplant Recipients With More Than 10 Years of ImmunosuppressionNot yet recruitingNCT07858201Not applicable
- A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsRecruitingNCT06270706Phase 12 countries
- DESTINY-PANTUMOUR04RecruitingNCT071240001 country
- EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.RecruitingNCT06263088Not applicable1 country
- Shortening Radiation Course Duration Using Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing and Concurrent Chemotherapy for High-Risk Anal Squamous Cell CarcinomaEnrolling by invitationNCT07775209Phase 21 country
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell CarcinomasRecruitingNCT07217171Phase 11 country
- Mind-Body Sexual Well-Being Program for Female GI Cancer SurvivorsNot yet recruitingNCT07795801Not applicable1 country
- A Study of IDP-001 in Advanced or Metastatic Solid TumorsRecruitingNCT07602842Phase 1/21 country
- Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)RecruitingNCT077821641 country
- Swabs in Screening for HPV (SWISH)Not yet recruitingNCT07790601Not applicable1 country
- ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal CancerRecruitingNCT07425054Phase 21 country
- Radiation Therapy for the Treatment of Metastatic Gastrointestinal CancersRecruitingNCT04221893Not applicable1 country
- Disease Evolution and Risk Factors of AIDS-related Prevalent CancersNot yet recruitingNCT07696169
- Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell CarcinomaRecruitingNCT07692152Phase 31 country
- Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell CancerNot yet recruitingNCT07680088Phase 2
- Integrated Cancer Repository for Cancer ResearchRecruitingNCT020126991 country
- MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized ApproachRecruitingNCT06050707Phase 23 countries
- Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related CancersRecruitingNCT056635021 country
- Blood Biomarkers Based Screening for HPV-driven OPCNot yet recruitingNCT06528353Not applicable
- Self-sampling to Optimize Anal Lesion OutcomesRecruitingNCT07192055Not applicable1 country
- Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure ProphylaxisRecruitingNCT07029152Not applicable1 country
- Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer:ChaseRecruitingNCT07555678Phase 21 country
- Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal CancerRecruitingNCT07407647Phase 21 country
- Assessment of Sexual Quality of Life Following Local Treatment (Radiotherapy With or Without Surgery) in Patients With HPV-positive Pelvic Cancer: a Descriptive Longitudinal StudyNot yet recruitingNCT07523152Not applicable
- Intrafractional Vaginal Dilation in Anal Cancer Patients Undergoing Pelvic RadiotherapyRecruitingNCT04094454Not applicable1 country
- Detecting HPV DNA in Anal and Cervical CancersRecruitingNCT048575281 country
- Virtual Reality for GI Cancer Pain to Improve Patient Reported OutcomesRecruitingNCT04907643Not applicable1 country
- HPV Genotype Attribution and Disease Burden of Anal Cancer in ChinaRecruitingNCT066704951 country
- Adaptive Radiation in Anal CancerRecruitingNCT05838391Not applicable1 country
- Ganglion Impar Neurolysis for the Improvement of Radiation-Induced Pain During Localized Anal or Perianal Skin Cancer TreatmentRecruitingNCT07112690Not applicable1 country
- An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)AvailableNCT06910137
- Beyond Survival: Addressing Gynecological and Sexual Health in Women After Radiotherapy for Anal CancerRecruitingNCT072962371 country
- Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of High-grade Lesions and/or Anal Cancer 10 Years After Inclusion in the ANRS IPERGAY TrialRecruitingNCT06522256Not applicable1 country
- A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid TumorsRecruitingNCT05941507Phase 1/22 countries
- Deciphering Mechanisms Underlying Cancer ImmunogenicityRecruitingNCT03958240Not applicable1 country
- Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCARecruitingNCT06207981Phase 32 countries
- Patient Reported Outcomes (PROs) in Anal Cancer Patient Treated by Intensity Modulated Radiotherapy (IMRT).RecruitingNCT063645791 country
- Identification of the Pathogenetic Mechanisms Underlying Squamous Cell CarcinomasRecruitingNCT062364641 country
- Determining the Frequency of Occurrence and Defining the Most Appropriate Screening Test for Anal Intraepithelial Neoplasia (AIN) in Patients With Human Papillomavirus (HPV) Related Gynecological Diseases.RecruitingNCT06574087Not applicable1 country
- Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.RecruitingNCT03061435Not applicable1 country